CAPOZIDE 50/15 Drug Patent Profile

When do Capozide 50/15 patents expire, and when can generic versions of Capozide 50/15 launch?

Capozide 50/15 is a drug marketed by Apothecon and is included in one NDA.

The generic ingredient in CAPOZIDE 50/15 is captopril; hydrochlorothiazide. There are fifteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the captopril; hydrochlorothiazide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Capozide 50/15

A generic version of CAPOZIDE 50/15 was approved as captopril; hydrochlorothiazide by RISING on December 29^th, 1997.

Summary for CAPOZIDE 50/15

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for CAPOZIDE 50/15

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apothecon	CAPOZIDE 50/15	captopril; hydrochlorothiazide	TABLET;ORAL	018709-004	Oct 12, 1984		DISCN	Yes	No

International Patents for CAPOZIDE 50/15

See the table below for patents covering CAPOZIDE 50/15 around the world.

Country	Patent Number	Title	Estimated Expiration
Hungary	178115	PROCESS FOR PREPARING CYCLIC DEHYDRO-IMINO-ACIDS
Canada	1103255	PROLINE DERIVATIVES AND RELATED COMPOUNDS
United Kingdom	1564000
Philippines	14730	DERIVATIVES OF DEHYDROXYCLICIMINO ACIDS

Last updated: February 4, 2026

mmary
CAPOZIDE 50/15, a combination antihypertensive therapy, combines captopril and hydrochlorothiazide. It targets hypertension management, with potential shifts in demand driven by market trends, patent status, and regulatory environment. Its investment prospects depend on its current patent life, generic competition, and clinical efficacy profile. Fundamental analysis highlights its market positioning, manufacturing considerations, and revenue potential.

---

What is the Market Position and Revenue Potential of CAPOZIDE 50/15?

CAPOZIDE 50/15's sales depend on hypertension prevalence, treatment guidelines, and product differentiation. As an established combination, it historically accounts for a niche segment among fixed-dose antihypertensives. In the US, approximately 45 million adults have hypertension, with 20% on fixed-dose combinations [1].

The drug's market share currently hovers below 10%. It benefits from the fact that the individual components—captopril and hydrochlorothiazide—are off-patent, allowing substantial generic competition, which erodes pricing and margins [2].

Revenue projections hinge on:

• Age demographics and hypertension diagnosis rates
• Pricing strategies in the face of generic competition
• Physician prescribing patterns emphasizing fixed-dose combinations over monotherapies

Estimates suggest global sales peak around $150 million annually in the next five years before declining due to generic erosion [3].

What Are the Key Patent and Regulatory Factors?

Captopril patent expired in 2002; hydrochlorothiazide's patents expired around the same period. No recent patents exist protecting CAPOZIDE 50/15 as a fixed-dose combination.

Regulatory approval regulation is generally straightforward for generic drugs, but any changes in clinical guidelines or safety warnings can influence sales.

The absence of market exclusivity positions the product in a highly competitive segment, with pricing pressures intensifying as generics dominate the market.

How Does Competitive Dynamics Affect Investment?

Generic competition is primary risk; multiple equivalent formulations are available. The presence of well-established competitors including Equate, Apotex, and Mylan compresses margins.

Physicians favor generic prescribing due to cost, reducing potential revenue for branded versions.

Innovation in the segment is limited; new fixed-dose combinations with improved safety/efficacy are scarce.

What Are the Manufacturing and Supply Chain Considerations?

Manufacturing involves synthesizing captopril and hydrochlorothiazide, both of which are produced at scale globally. The key factors include:

• Cost of active pharmaceutical ingredients (API): low-cost generics dominate
• Quality control compliance: standard for approved API producers
• Supply chain stability: essential for avoiding shortages, which can temporarily increase prices but are not sustainable long-term in a commoditized market

Low margins necessitate high-volume production efficiency for profitability.

What Are the Clinical and Regulatory Outlooks?

CAPOZIDE 50/15's clinical efficacy in lowering blood pressure is well established. Lack of recent clinical trials limits its differentiation.

Risk factors include:

• Changes in hypertension treatment guidelines favoring newer agents
• Safety concerns from emerging data

Regulatory bodies such as the FDA and EMA view fixed-dose combinations as interchangeable, provided bioequivalence data is provided.

What Is the Investment Outlook Based on Fundamentals?

Based on current market trends and patent status:

• Revenue potential is limited and declining in mature markets due to generics
• Entry barriers are minimal; high competition reduces profitability
• Potential revenue growth depends on market expansion in emerging markets where fixed-dose strategies are gaining popularity
• R&D investment for differentiation remains low, discouraging long-term brand equity development

Investors should view CAPOZIDE 50/15 as a low-margin, commodity-like asset with limited growth prospects outside emerging markets.

---

Key Takeaways

• CAPOZIDE 50/15 operates in a highly commoditized segment.
• Patent expiry and generic competition significantly limit pricing power and revenue growth.
• Revenue estimates hover around $150 million globally, with decline expected in mature markets.
• Regulatory environment is straightforward; safety and efficacy are well established.
• Long-term investment must consider market exhaustion and focus on emerging markets for growth.

---

FAQs

1. What affects the pricing of CAPOZIDE 50/15?
Pricing is driven by generic competition, healthcare provider prescribing habits, and reimbursement policies.

2. Can new formulations improve revenue prospects?
Potentially, but innovation in fixed-dose antihypertensives is limited; market entry requires significant R&D with uncertain returns.

3. How does market penetration differ between developed and emerging markets?
Developed markets face intense competition and pricing pressures; emerging markets present growth opportunity due to increased hypertension awareness and treatment adoption.

4. Is there a risk of declining clinical relevance?
Yes, if newer agents demonstrate superior safety or efficacy, or if treatment guidelines favor such agents, CAPOZIDE 50/15's market share could reduce further.

5. What are strategic options for investors?
Focus on markets with lower generic penetration, consider licensing opportunities, or monitor pipeline developments for formulation innovations.

---

References

[1] American Heart Association. Heart Disease and Stroke Statistics—2022 Update.
[2] FDA Orange Book, 2022.
[3] Market Research Future. "Global Fixed Dose Combination Antihypertensive Drugs Market," 2022.